Potential 2016 Q1 valuation for new investors400mm in projected revenue in US alone - with EU you can double that. There is a huge shortage of BCG (frontline for Bladder Cancer) Both Merck and Sanofi have shut down plants. Doctors are now prescribing 1/3 and 1/2 BCG doses to spread around the inventory. Only 1.5% of MCNA patients experienced mild to moderate AE in 3.5 trials. BCG is well over 30% AE. With no live pathogens, MCNA can be administered by a lab tech immediately following Post TURBT (BCG cannot be administered for 2 weeks post TURBT)with impressive results (around 40% CRR). If MCNA is approved for refractory BC, that 400mm number will swell enormously with off label use. Pfizer paid almost 6 x revenue for Abbvie, but most recent pharma acquisitions have been average 4.6 x revenue. Using 400mm peak revenue and a 4 x revenue multiplier valuation is 1.6B USD. $6.67 USD/ share ($8.54 / share CDN) With huge player Consonance Capital taking almost a 20% (at market - with no warrants)stake in the company, good things are afoot. It all starts September with FDA giving us the priority review and thumbs up on our submission. fingers crossed. GLTA